|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greef B and Eisen T: Medical treatment of
renal cancer: New horizons. Br J Cancer. 115:505–516. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Powles T, Staehler M, Ljungberg B,
Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M,
Kuczyk MA, et al: Updated EAU guidelines for clear cell renal
cancer patients who fail VEGF targeted therapy. Eur Urol. 69:4–6.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schödel J, Grampp S, Maher ER, Moch H,
Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible
transcription factors and renal cancer. Eur Urol. 69:646–657. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bramham CR, Jensen KB and Proud CG: Tuning
specific translation in cancer metastasis and synaptic memory:
Control at the MNK-eIF4E axis. Trends Biochem Sci. 41:847–858.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo J, Chakraborty AA, Liu P, Gan W, Zheng
X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M, et al: pVHL
suppresses kinase activity of Akt in a
proline-hydroxylation-dependent manner. Science. 353:929–932. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luan FL, Ding R, Sharma VK, Chon WJ,
Lagman M and Suthanthiran M: Rapamycin is an effective inhibitor of
human renal cancer metastasis. Kidney Int. 63:917–926. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Achermann C, Stenner F and Rothschild SI:
Treatment, outcome and prognostic factors in renal cell carcinoma-a
single center study (2000–2010). J Cancer. 7:921–927. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Makhov PB, Golovine K, Kutikov A, Teper E,
Canter DJ, Simhan J, Uzzo RG and Kolenko VM: Modulation of Akt/mTOR
signaling overcomes sunitinib resistance in renal and prostate
cancer cells. Mol Cancer Ther. 11:1510–1517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naito S, Makhov P, Astsaturov I, Golovine
K, Tulin A, Kutikov A, Uzzo RG and Kolenko VM: LDL cholesterol
counteracts the antitumour effect of tyrosine kinase inhibitors
against renal cell carcinoma. Br J Cancer. 116:1203–1207. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ichiyanagi O, Naito S, Ito H, Kabasawa T,
Narisawa T, Kanno H, Kurota Y, Kurokawa M, Fukuhara H, Sakurai T,
et al: Levels of 4EBP1/eIF4E activation in renal cell carcinoma
could differentially predict its early and late recurrence. Clin
Genitourin Cancer. 16:e1029–e1058. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Armengol G, Rojo F, Castellvi J, Iglesias
C, Cuatrecasas M, Pons B, Baselga J and Ramón y Cajal S: 4E-binding
protein 1: A key molecular ‘funnel factor’ in human cancer with
clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
No JH, Jeon YT, Park IA, Kim YB, Kim JW,
Park NH, Kang SB, Han JY, Lim JM and Song YS: Activation of mTOR
signaling pathway associated with adverse prognostic factors of
epithelial ovarian cancer. Gynecol Oncol. 121:8–12. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Coleman LJ, Peter MB, Teall TJ, Brannan
RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V,
Verghese ET, et al: Combined analysis of eIF4E and 4E-binding
protein expression predicts breast cancer survival and estimates
eIF4E activity. Br J Cancer. 100:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Campbell L, Jasani B, Griffiths DF and
Gumbleton M: Phospho-4e-BP1 and eIF4E overexpression
synergistically drives disease progression in clinically confined
clear cell renal cell carcinoma. Am J Cancer Res. 5:2838–2848.
2015.PubMed/NCBI
|
|
21
|
Joshi S and Platanias LC: Mnk kinase
pathway: Cellular functions and biological outcomes. World J Biol
Chem. 5:321–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakai Y, Miyake M, Morizawa Y, Hori S,
Tatsumi Y, Anai S, Onishi S, Tanaka N and Fujimoto K: Potential
biomarkers for the therapeutic efficacy of sorafenib, sunitinib and
everolimus. Oncol Rep. 37:227–234. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beuselinck B, Vano YA, Oudard S, Wolter P,
De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J,
Debruyne PR, et al: Prognostic impact of baseline serum C-reactive
protein in patients with metastatic renal cell carcinoma (RCC)
treated with sunitinib. BJU Int. 114:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
